
News|Articles|November 1, 2012
Pipeline Preview
Recent FDA action (through October 2012) related to, Treprostinil diethanolamine extended release tablets, Lomitapide, Mipomersen sodium, Xilonix, Ponatinib, Trospium chloride extended-release capsules
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Schizophrenia, Bipolar Disorder, and MDD Linked to Increased Risk for Developing Long COVID
2
Health Plans Beware: Keep Contract Language Tight If Your PBM Wants Rebate Guarantees Renegotiated Because of the IRA and Biosimilars | AMCP Nexus 2025
3
PBMs Make a Case for the GLP-1 Teeter Totter: Up on the Pharmacy Benefit, Down on the Medical One | AMCP Nexus 2025
4
Lumakras Can Trigger ILD. New Findings Suggest Why
5

















































